From: 12, Manual therapies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Study | Applicability | Limitations | Other comments | Cost (a) | Effects (a) | Incremental costs (b) | Incremental effects (b) | Cost effectiveness (b) | Uncertainty |
---|---|---|---|---|---|---|---|---|---|
Beam 2004498 (UK) | Partially applicable (c) | Potentially serious limitations (d) |
| 1. £346(e) | 1. 0.618 QALYs | Baseline | Prob. CE: 0%/0% | ||
2. £486(e) | 2. 0.635 QALYs | Dominated by 4 | Prob. CE: ∼7%/∼7% | ||||||
4. £471(e) | 4. 0.651 QALYs | 4 vs1: £126(e) | 0.033 QALYs | £3800 per QALY gained | Prob. CE:∼38%/∼37% | ||||
3. £541(e) | 3. 0.659 QALYs | 3 versus 4: £70 (e) | 0.008 QALYs | £8700 per QALY gained | Prob. CE: ∼54%/∼57% | ||||
| 2-1:£195 (e) | 2-1: 0.041 QALYs | 2 versus 1: £4800 per QALY gained | Probability intervention 2 cost-effective (£20K/30K threshold): >95%/100% Increasing cost of manipulation to that of private provider did not change conclusions. | |||||
| 2-1:£140 (e) | 2-1: 0.017 QALYs | 2 versus 1: £8300 per QALY gained | Probability intervention 2 cost-effective (£20K/30K threshold): ∼60%/∼70% Increasing cost of manipulation to that of private provider did not change conclusions. |
ICER = incremental cost effectiveness ratio; n/a = not available; RCT = randomised clinical trial; QALY = quality-adjusted life year; Prob. CE= Probability intervention is cost-effective at a £20,000/£30,000 threshold.
When more than two comparators, Intervention number in order of least to most effective in terms of QALYs. When there are two comparators it will be blank.
When more than two comparators, this is a full incremental analysis of available strategies: first strategies are ruled out that are dominated (another strategy is more effective and has lower costs) or subject to extended dominance (the strategy is more effective and more costly but the incremental cost effectiveness ratio is higher than the next most effective option and so it would never be the most cost effective option); incremental costs, incremental effects and incremental cost effectiveness ratios are calculated for the remaining strategies by comparing each to the next most effective option. The most cost effective option is that with the highest QALYs with an ICER below £20,000 per QALY gained.
Resource use data (1999-2002) and unit costs (2000/01) may not reflect the current NHS context. Study does not include all non-invasive treatment options.
A longer time horizon may be preferable given than interventions continued to show benefit at 12 months. Within-trial analysis and so does not reflect full body of available evidence for this intervention; although is the only study with these exact comparison of combinations.
Cost components incorporated: interventions, primary care contacts (GP, practice nurse, physiotherapist, other), secondary care contacts (hospital admissions and outpatient appointments).
From: 12, Manual therapies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.